Voy's testosterone ads banned for misleading health claims, says ASA
The Advertising Standards Authority has banned five ads from Voy for misleading claims linking common symptoms to low testosterone levels. This ruling emphasizes the need for accurate health advertisโฆ
The Advertising Standards Authority (ASA) has banned five advertisements from online healthcare provider Voy for making misleading claims about low testosterone levels in men. The adverts, which promoted Voy's at-home testosterone blood tests, included three posters and two paid Facebook ads that linked common symptoms like irritability and fatigue to low testosterone.
This action comes amid growing scrutiny of advertisements targeting men's health. The ASA's decision follows similar rulings against other companies in August for making unsubstantiated claims regarding testosterone testing services. The regulator has noted a troubling trend among advertisers who exploit insecurities around male health issues, particularly those related to libido and aging. The NHS has indicated that while testosterone levels decline with age, this decrease is generally not linked to significant health problems in itself. They assert that symptoms often attributed to low testosterone can arise from various factors.
Voy has stated that it withdrew the contested adverts while the investigation was ongoing and will not use them again. The ASA highlighted specific examples of misleading claims, including one asserting that "low testosterone sneaks up on 1 in 4 men over 30," which lacked supporting evidence. Voy's chief medical officer, Dr. Earim Chaudry, defended the company's advertising practices, stating that all patient decisions are clinician-led and that they continuously review their marketing strategies to comply with UK standards.
The ASA's ruling underscores the importance of accuracy in health advertising, especially as it pertains to sensitive topics like testosterone levels. Businesses are reminded that while advertising for testosterone testing is permissible, all claims must be substantiated with reliable evidence. The ongoing investigation into this sector may lead to further accountability measures aimed at protecting consumers from misleading health information.
Read Full Story at BBC Health โ

